INTRODUCTION
============

*Helicobacter pylori* was classified as a Group 1 carcinogen in human gastric carcinogenesis.[@b1-gnl-10-902] The overall estimate of *H. pylori* seroprevalence in middle aged adults is 74% in developing countries and 58% in developed countries. Eastern Asia including Korea showed 55% to 64% prevalence of *H. pylori* seropositivity.[@b2-gnl-10-902] Besides its well-known relation to gastric adenocarcinoma, *H. pylori* has been also linked with various extragastric malignancies. One of the most interesting and so far best analyzed associations is *H. pylori* and colorectal neoplasm (CRN).[@b3-gnl-10-902],[@b4-gnl-10-902] It was the first recognized that CRN was associated with an increased prevalence of *H. pylori* infection in the 1990s.[@b5-gnl-10-902] However, the association between *H. pylori* and CRN was inconsistent between studies. Although some studies demonstrated modest association between *H. pylori* and CRN,[@b6-gnl-10-902]--[@b9-gnl-10-902] others did not show the positive relationship.[@b10-gnl-10-902],[@b11-gnl-10-902]

Gastric mucosal atrophy is a late sequela from chronic *H. pylori* infection. The long-term presence of *H. pylori* infection leads to atrophic gastritis (AG) in 8.1% of patients per year[@b12-gnl-10-902] and is associated with a 10-fold increased risk of AG.[@b13-gnl-10-902] Premalignant gastric lesions such as AG or dysplasia had a significant risk of gastric cancer[@b14-gnl-10-902] and gastric cancer and/or adenoma was associated with higher prevalence of colorectal cancer and adenoma.[@b15-gnl-10-902] However, the correlation between *H. pylori*-related AG and CRN has been investigated only in a limited number of studies and it is inconclusive whether AG increases the risk of CRN. One study showed an insignificant association between colon cancer and AG diagnosed by pepsinogen I/II ratio or histology.[@b11-gnl-10-902] In contrast, a recent study showed that intestinal metaplasia, which is usually accompanied by AG, was strongly associated with any type of CRN.[@b16-gnl-10-902]

Therefore, the present study was to investigate the association between *H. pylori* infection and CRN, especially, advanced CRN. Furthermore, we aimed to evaluate whether AG plays some role in the relation between *H. pylori* infection and advanced CRN.

MATERIALS AND METHODS
=====================

1. Study design and population
------------------------------

This retrospective cross-sectional study was conducted using a consecutive series of subjects who underwent screening colonoscopy and *H. pylori* serology testing as part of a health checkup program from January 2012 to November 2013 at the Health Screening and Promotion Center in Asan Medical Center, Seoul, Korea. All subjects to be screened provided informations to a standard questionnaire regarding their personal medical history including colorectal cancer, present medications, family history of colorectal cancer in first-degree relatives, and lifestyle such as smoking and alcohol consumption. Physical examinations, laboratory assays, imaging studies, and colonoscopy were performed after fasting for at least 12 hours. The examination data were recorded in a centralised electronic medical record system. Endoscopic findings and pathologic findings were recorded as coding system as well as descriptive form in electronic medical record system.

We excluded subjects who had a history of *H. pylori* eradication, a history of colorectal cancer, incomplete colonoscopy due to poor bowel preparation and cecal intubation failure, and unavailable esophagogastroduodenoscopy (EGD) data. The Institutional Review Board of the Asan Medical Center (Seoul, Korea) approved this study (IRB No. 2013-1072).

2. Physical parameters and laboratory assays
--------------------------------------------

Waist circumference, blood pressure, triglyceride level, high-density lipoprotein cholesterol level, fasting glucose level, and medical history were obtained to evaluate the presence of metabolic syndrome. Metabolic syndrome was defined as having at least three of the criteria set by the National Cholesterol Education Programme/Adult Treatment Panel III criteria, as updated by the American Heart Association/National Heart, Lung, and Blood Institute.[@b17-gnl-10-902] The body mass index (BMI) was calculated as the weight in kilograms divided by the square of the height in meters. Obesity was defined as a BMI ≥25 kg/m^2^.[@b18-gnl-10-902]

*H. pylori* serology testing was performed on the same day as the colonoscopy. Immunoglobulin G (IgG) antibody to *H. pylori* (Anti-*H. pylori* IgG Ab) were measured using IMMULITE 2000 *H. pylori* IgG produced by SIEMENS (Siemens Healthcare Diagnostics Products Ltd., Llanberis, UK) and a qualitative chemiluminescent immunometric assay. A subject was considered *H. pylori* infected when the *H. pylori*-IgG level was higher than 1.0 U/mL.

3. Assessment of endoscopic findings
------------------------------------

All EGD and colonoscopy were performed by board certified gastrointestinal endoscopists. All the EGDs were performed with GIF-H260 (Olympus Optical Co., Ltd., Tokyo, Japan). All the colonoscopies were performed with CF-H260AI (Olympus Optical Co., Ltd.). During colonoscopy, the location, number, and size (estimated with opened biopsy forceps) of CRN were recorded. All CRN were biopsied or polypectomized and histologically evaluated. The histopathology of CRN was classified according to the World Health Organization classification.[@b19-gnl-10-902] Advanced colorectal adenoma was defined as an adenoma that was ≥1 cm in diameter, had high-grade dysplasia, significant villous component or any combination thereof. Advanced CRN was defined as advanced adenoma and/or invasive cancer. The location of CRN was defined as distal colon (descending colon and rectosigmoid colon) and proximal colon (from cecum to splenic flexure).

Gastric mucosal atrophy was suggested when EGD findings showed whitish to yellowish mucosal color change, visible submucosal vessels, and/or absence of rugae.[@b20-gnl-10-902] The extent of atrophy was classified into a closed type and an open type based on Kimura and Takemoto criteria.[@b20-gnl-10-902] The closed type means that the atrophic border remains on the lesser curvature of the stomach, while the O-type means that the atrophic border no longer exists on the lesser curvature but extends along the anterior and posterior walls of the stomach.[@b20-gnl-10-902] In our study, AG was defined when the extent of atrophy showed the open type. Endoscopists recorded EGD findings and entered the diagnostic code into the electronic medical record system.

4. Statistical analysis
-----------------------

Clinical and endoscopic variables between groups are summarized as means and standard deviations for continuous variables or frequency (%) for categorical variables. Associations of clinical and endoscopic variables with advanced CRN were tested using univariate logistic regression followed by multivariate analysis. Results are reported as odds ratios (ORs) and 95% confidence interval (CI). All reported p-values were two-sided and p-values less than 0.05 were considered to indicate statistical significance. All statistical analyses were performed using SPSS^®^ Statistics version 21.0 (IBM Corp., Armonk, NY, USA).

RESULTS
=======

1. Baseline characteristics of the study population
---------------------------------------------------

From January 2012 to November 2013, a consecutive series of 7,517 participants ≥40 years of age who underwent screening colonoscopy were eligible for this study. A total of 6,351 subjects were included in the final analysis after exclusion of 1,166 participants because of a history of *H. pylori* eradication, incomplete colonoscopy, unavailable EGD data, and a history of colorectal cancer ([Fig. 1](#f1-gnl-10-902){ref-type="fig"}).

The mean age of the 6,351 study patients was 51.7±8.1 years and 3,491 subjects (54.9%) were 50 years or older. Male comprised 52.8% of the population. A total of 2,497 subjects (39.2%) had CRN and 316 (5.0%) had advanced CRN. AG was reported in 1,989 subjects (31.3%). Detailed baseline characteristics are presented in [Table 1](#t1-gnl-10-902){ref-type="table"}.

2. Association between *H. pylori* infection and CRN
----------------------------------------------------

Of a total 6,351 subjects, the *H. pylori*-seropositivity was shown in 3,896 (61.3%). The prevalence of overall CRN in subjects with *H. pylori* infection was significantly higher than those without *H. pylori* infection (41.9% vs 35.2%, p\<0.001). The prevalence of advanced CRN in subjects with *H. pylori* infection was significantly higher than those without *H. pylori* infection (5.7% vs 3.9%, p=0.001) ([Table 1](#t1-gnl-10-902){ref-type="table"}). On the univariate analysis, male gender, older age, a family history of colorectal cancer, smoker, alcohol consumption, metabolic syndrome, BMI ≥25 kg/m^2^ and *H. pylori* infection were significantly associated with overall and advanced CRN ([Table 2](#t2-gnl-10-902){ref-type="table"}). In logistic regression multivariate analysis, *H. pylori* infection was an independent risk factor of overall and advanced CRN. The OR of *H. pylori* infection for advanced CRN was 1.34 (95% CI, 1.04 to 1.72; p=0.023). Male gender, older age, a family history of colorectal cancer, smoking of ≥20 pack year, and metabolic syndrome were also significantly associated with advanced CRN ([Table 2](#t2-gnl-10-902){ref-type="table"}).

3. Association between *H. pylori* infection, AG, and advanced CRN
------------------------------------------------------------------

A total of 6,351 subjects were classified according to the status of *H. pylori* infection and AG on EGD; 2,148 were *H. pylori* (−) AG (−), 307 were *H. pylori* (−) AG (+), 2,214 were *H. pylori* (+) AG (−), and 1,682 were *H. pylori* (+) AG (+). *H. pylori* (+) AG (+) group showed significantly higher prevalence of overall CRN and advanced CRN ([Table 3](#t3-gnl-10-902){ref-type="table"}).

After logistic regression, *H. pylori* (+) AG (−) was associated with multiple adenomas (OR, 1.38; 95% CI, 1.06 to 1.79; p=0.017) and proximal CRN (OR, 1.20; 95% CI, 1.04 to 1.39; p=0.013) ([Table 3](#t3-gnl-10-902){ref-type="table"}). *H. pylori* (−) AG (+) was associated with high-grade dysplasia, multiple adenomas and proximal CRN. *H. pylori* (+) AG (+) was significantly associated with advanced CRN, villous adenoma, ≥1 cm sized adenoma, high-grade dysplasia, multiple adenomas and proximal CRN.

After adjustment with confounding factors including age, gender, family history of colorectal cancer, BMI, metabolic syndrome, smoking status and amount of alcohol consumption, *H. pylori* (+) AG (+) was independently associated with advanced CRN (OR, 1.40; 95% CI, 1.03 to 1.91; p=0.030) ([Table 4](#t4-gnl-10-902){ref-type="table"}). In addition, *H. pylori* (+) AG (+) was associated with high-grade dysplasia, multiple adenomas and proximal CRN. However, *H. pylori* (−) AG (+) was not an independent risk factor for any types of CRN. *H. pylori* (+) AG (−) also did not show any independent association with CRN except equivocal risk for overall CRN (OR, 1.13; 95% CI, 0.99 to 1.29; p=0.057) and slightly increased risk of proximal CRN (OR, 1.17; 95% CI, 1.01 to 1.36; p=0.036) ([Table 4](#t4-gnl-10-902){ref-type="table"}).

DISCUSSION
==========

Our cross-sectional study demonstrated that *H. pylori* infection was an independent risk factor of advanced CRN. We found that this increased risk of advanced CRN by *H. pylori* infection was evident only in the presence of AG.

The association between *H. pylori* infection and CRN has been inconclusive. Several meta-analyses and large population based studies showed the positive association between *H. pylori* and CRN.[@b6-gnl-10-902]--[@b8-gnl-10-902],[@b21-gnl-10-902],[@b22-gnl-10-902] However, other studies did not find any relationship between *H. pylori* and CRN or showed limited associations only in women.[@b10-gnl-10-902],[@b11-gnl-10-902] The reason for this inconsistency between studies is not clear. Many diagnostic tests for *H. pylori* such as serological test, histological examination, the urea breath test and the rapid urease test are currently available. Difference in methods of *H. pylori* detection between studies might contribute to the inconsistent results about the relation between *H. pylori* and CRN. Another reason for inconsistent findings between studies may be related to different study participants and small sample sizes. Unlike absence of association between *H. pylori* and CRN in previous small sized, hospital based studies,[@b10-gnl-10-902],[@b11-gnl-10-902] a recent large scale (n=2,195) cross-sectional study using *H. pylori* IgG serology showed 2.21-fold higher prevalence of advanced CRN in the *H. pylori* (+) group.[@b6-gnl-10-902] A large population based case-control study which enrolled 1,669 controls and 1,712 patients with colorectal cancer also showed the positive association between *H. pylori* and colorectal cancer.[@b7-gnl-10-902] In our large cohort including 6,351 subjects, we found *H. pylori* infection was a significant, independent risk factor for advanced CRN with OR 1.34 ([Table 2](#t2-gnl-10-902){ref-type="table"}). We suggest that large study population should be necessary in this kind of study, especially in Asia, because high prevalence of *H. pylori* colonization in Eastern countries may conceal an association between *H. pylori* and CRN if the association is modest.

Our study showed that advanced CRN occurred more frequently in *H. pylori* infected patients with AG than without AG (7.3% vs 4.4%, p\<0.001). After adjustment with confounders, *H. pylori* (+) AG (+) was still independently associated with advanced CRN, but *H. pylori* (+) AG (−) was not. This finding is consistent with another recent study which showed that the *H. pylori*-positive gastritis and intestinal metaplasia, a more easily recognizable form of mucosal atrophy, increased risk for CRN while *H. pylori*-negative gastritis did not.[@b16-gnl-10-902] Although other studies did not show the relation between AG and CRN, these negative studies excluded those with *H. pylori* infection or did not analyze *H. pylori* infection status.[@b23-gnl-10-902] Thus we believe that AG accompanied by *H. pylori* infection may be positively associated with advanced CRN. In addition, when considering *H. pylori* (+) AG (−) did not increase the risk of advanced CRN, long-standing *H. pylori* infection may be crucial for development of advanced CRN because AG is usually a chronic sequela of *H. pylori* infection. In fact, our data also showed mean age was older in *H. pylori* (+) AG (+) group than in *H. pylori* (+) AG (−) group (55.2 years vs 49.8 years), which suggests *H. pylori* (+) AG (+) group may have suffered from longer period of *H. pylori* infection because the acquisition of *H. pylori* in Korean population is presumed to be early in their lives and almost similar throughout the population.[@b24-gnl-10-902] Persistent exposure to *H. pylori* infection directly increased gastrin secretion.[@b25-gnl-10-902] Moreover, persistent exposure to *H. pylori* induced atrophic changes of the gastric body mucosa, which resulted in increased level of serum gastrin by feedback of low acid output on the antral G cell.[@b26-gnl-10-902] Gastrin has a trophic effect on epithelial cell growth and proliferation, which can contribute to colorectal carcinogenesis.[@b27-gnl-10-902] Others speculated that hypochlorhydria caused by *H. pylori*-related AG might lead to bacterial overgrowth in the gastrointestinal tract and alterations in the colonic microenvironment of the bacterial flora.[@b28-gnl-10-902] Additionally, hypochlorhydria may result in an increase in unabsorbed nutrients in the lower intestine due to impaired gastric protein digestion.[@b29-gnl-10-902] Therefore, some metabolites such as hydrogen sulfide, ammonia or phenol which can derive from fermentation of malabsorbed proteins by overgrown bacteria probably play a role in the pathogenesis of CRN.

In our study, *H. pylori* (−) AG (+) was not an independent risk factor for any types of CRN. Some portion of patients with *H. pylori* (−) AG (+) may represent a group of severe AG following long-term *H. pylori* infection. Thus, this group may show hypergastrinemia and, theoretically, higher risk of CRN. Despite this hypothetical reasoning, our study did not show any correlation. We suggest that the relatively small number (n=307) and older age of the *H. pylori* (−) AG (+) group might mask the probable influence on CRN in the multivariate analysis. When we performed a multivariate analysis after exclusion of age factor, *H. pylori* (−) AG (+) group was an independent risk factor for CRN with high-grade dysplasia (data not shown).

In this study, *H. pylori* infection, especially with the presence of AG, increased the risk of proximal CRN. This finding is consistent with a previous study.[@b8-gnl-10-902] The risk of CRN associated with proximal and distal CRN are different in environmental risk factors and genetic alterations.[@b30-gnl-10-902] CpG island methylator phenotype and microsatellite instability are shown predominantly in the proximal CRN and altered DNA methylation is more frequently involved in the carcinogenic process of the proximal colon.[@b31-gnl-10-902] We suggest AG induced colonic bacterial overgrowth may generate methylation changes more easily in the proximal colon. In addition, colonic bacterial overgrowth leads to an enhanced production of secondary bile acids which can increase the risk for proximal colon cancer.[@b32-gnl-10-902] This finding may further explain our results of increased risk of proximal CRN in those with *H. pylori*-related AG.

Our study had several limitations. First, we diagnosed AG endoscopically based on Kimura and Takemoto criteria[@b20-gnl-10-902] without histologic diagnosis, which is not completely objective. Therefore, there may be interobserver variability regarding the diagnosis of AG.[@b33-gnl-10-902] Although we could not investigate the interobserver variability because of the retrospective study design, we suggest the variability might not be high because all the endoscopists who performed the study EGD and colonoscopies were board-certified gastrointestinal endoscopists. Second, *H. pylori* infection was assessed by the serology test, which cannot accurately reflect the current *H. pylori* infection. Third, serum gastrin level was not obtained which could explain key mechanisms how *H. pylori* affect the development of CRN. Finally, this study was a single center investigation which requires further studies in other nations and ethnic groups before generalization of the conclusion. Despite these limitations, our study has strength that we analyzed the relation not only between *H. pylori* infection and CRN but also further investigated the role of AG.

In conclusion, this study indicated that *H. pylori* infection increased the risk of overall and advanced CRN. When *H. pylori* infection status was stratified by the presence of AG, only *H. pylori* (+) AG (+) group enhanced the risk of advanced CRN. Strict colonoscopy screening and surveillance may be warranted in those with endoscopic AG and *H. pylori* infection.
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###### 

Baseline Characteristics of the Study Population

  Characteristic                            All participants (n=6,351)   *H. pylori* (−) (n=2,455)   *H. pylori* (+) (n=3,896)   p-value
  ----------------------------------------- ---------------------------- --------------------------- --------------------------- ---------
  Male sex                                  3,353 (52.8)                 1,212 (49.4)                2,141 (55.0)                \<0.001
  Age, yr                                   51.7±8.1                     51.0±8.1                    52.1±8.1                    \<0.001
  Family history of CRC                     291 (4.6)                    98 (4.0)                    193 (5.0)                   0.074
  Body mass index ≥25 kg/m^2^               1,965 (30.9)                 741 (30.2)                  1,224 (31.4)                0.300
  Smoking habitus                                                                                                                0.011
   Never                                    3,551 (55.9)                 1,430 (58.2)                2,121 (54.4)                
   \<20 pack year                           980 (15.4)                   355 (14.5)                  625 (16.0)                  
   ≥20 pack year                            1,820 (28.7)                 670 (27.3)                  1,150 (29.5)                
  Alcohol consumption                                                                                                            0.056
   Never                                    1,744 (27.5)                 686 (27.9)                  1,058 (27.2)                
   \<20 g/day in women, \<40 g/day in men   3,336 (52.5)                 1,315 (53.6)                2,021 (51.9)                
   ≥20 g/day in women, ≥40 g/day in men     1,271 (20.0)                 454 (18.5)                  817 (21.0)                  
  Metabolic syndrome                        1,570 (24.7)                 562 (22.9)                  1,008 (25.9)                0.007
  Waist circumferences, cm                  83.2±9.6                     82.5±9.7                    83.3±9.4                    0.005
  Systolic blood pressure, mm Hg            122.9±15.8                   121.8±15.1                  123.6±16.2                  \<0.001
  Diastolic blood pressure, mm Hg           77.9±11.7                    77.2±11.5                   78.4±11.9                   \<0.001
  Fasting glucose, mg/dL                    98.9±22.3                    98.5±21.0                   99.1±23.0                   0.247
  Triglyceride, mg/dL                       118.3±82.3                   117.3±79.4                  118.9±84.1                  0.447
  HDL cholesterol, mg/dL                    56.0±14.7                    57.0±15.0                   55.4±14.4                   \<0.001
  Colonoscopy findings                                                                                                           
   Overall CRN                              2,497 (39.2)                 864 (35.2)                  1,633 (41.9)                \<0.001
   Advanced CRN                             316 (5.0)                    95 (3.9)                    221 (5.7)                   0.001
   Villous adenoma                          45 (0.7)                     13 (0.5)                    32 (0.8)                    0.177
   Size ≥1 cm                               270 (4.3)                    85 (3.5)                    185 (4.7)                   0.013
   High-grade dysplasia or cancer           51 (0.8)                     11 (0.4)                    40 (1.0)                    0.012
   No. of adenoma ≥3                        458 (7.2)                    132 (5.4)                   326 (8.4)                   \<0.001
  EGD findings                                                                                                                   
   AG                                       1,989 (31.3)                 307 (12.5)                  1,682 (43.2)                \<0.001
  Gastric pathology                                                                                                              0.019
   Gastric adenoma                          32 (0.5)                     9 (0.4)                     23 (0.6)                    
   High-grade dysplasia or cancer           23 (0.4)                     3 (0.1)                     20 (0.5)                    

Data are presented as number (%) or mean±SD. A chi-square test was used for categorical variables, and a t-test was used for continuous variables. *H. pylori*, *Helicobacter pylori*; CRC, colorectal cancer; HDL, high-density lipoprotein; CRN, colorectal neoplasm; EGD, esophagogastroduodenoscopy; AG, atrophic gastritis.

###### 

Risk Factors for Overall and Advanced Colorectal Neoplasm

                                             No. (n=6,351)   Overall CRN (n=2,497)   Advanced CRN (n=316)                                                                                                         
  ------------------------------------------ --------------- ----------------------- ---------------------- --------- ------------------- --------- ----------- ------------------- --------- ------------------- ---------
  Serum anti-*H. pylori* IgG antibody                                                                       \<0.001                       \<0.001                                   0.001                         0.023
   Negative                                  2,455           864 (35.2)              1                                1                             95 (3.9)    1                             1                   
   Positive                                  3,896           1,633 (41.9)            1.33 (1.19--1.48)                1.22 (1.09--1.36)             221 (5.7)   1.49 (1.17--1.91)             1.34 (1.04--1.72)   
  Sex                                                                                                       \<0.001                       \<0.001                                   \<0.001                       0.021
   Female                                    2,998           868 (29.0)              1                                1                             90 (3.0)    1                             1                   
   Male                                      3,353           1,629 (48.6)            2.32 (2.09--2.57)                1.77 (1.51--2.08)             226 (6.7)   2.34 (1.82--2.99)             1.55 (1.07--2.26)   
  Age, yr                                                                                                   \<0.001                       \<0.001                                   \<0.001                       \<0.001
   40--49                                    2,860           865 (30.2)              1                                1                             89 (3.1)    1                             1                   
   50--59                                    2,489           1,064 (42.7)            1.72 (1.54--1.93)      \<0.001   1.78 (1.58--1.99)   \<0.001   143 (5.7)   1.89 (1.45--2.48)   \<0.001   1.90 (1.44--2.50)   \<0.001
   ≥60                                       1,002           568 (56.7)              3.02 (2.60--3.50)      \<0.001   3.24 (2.76--3.80)   \<0.001   84 (8.4)    2.85 (2.09--3.87)   \<0.001   2.94 (2.12--4.06)   \<0.001
  Family history of CRC                                                                                     0.003                         0.003                                     0.01                          0.014
   Absent                                    6,060           2,358 (38.9)            1                                1                             292 (4.8)   1                             1                   
   Present                                   291             139 (47.8)              1.44 (1.13--1.81)                1.45 (1.13--1.86)             24 (8.2)    1.78 (1.15--2.74)             1.75 (1.12--2.72)   
  Body mass index, kg/m^2^                                                                                  \<0.001                       0.098                                     0.017                         0.794
   \<25                                      4,386           1,591 (36.3)            1                                1                             199 (4.5)   1                             1                   
   ≥25                                       1,965           906 (46.1)              1.50 (1.35--1.67)                1.11 (0.98--1.26)             117 (6.0)   1.33 (1.05--1.69)             0.96 (0.74--1.26)   
  Smoking habitus                                                                                           \<0.001                       0.001                                     \<0.001                       0.064
   Never                                     3,551           1,128 (31.8)            1                                1                             118 (3.3)   1                             1                   
   \<20 pack year                            980             428 (43.7)              1.67 (1.44--1.92)      \<0.001   1.18 (0.98--1.41)   0.076     61 (6.2)    1.93 (1.41--2.65)   \<0.001   1.47 (0.99--2.19)   0.054
   ≥20 pack year                             1,820           941 (51.7)              2.30 (2.05--2.58)      \<0.001   1.36 (1.15--1.61)   \<0.001   137 (7.5)   2.37 (1.84--3.05)   \<0.001   1.52 (1.06--2.19)   0.030
  Alcohol consumption                                                                                       \<0.001                       0.013                                     \<0.001                       0.168
   Never                                     1,744           621 (35.6)              1                                1                             72 (4.1)    1                             1                   
   \<20 g/day in women, \<40 g/day in men    3,336           1,254 (37.6)            1.09 (0.97--1.23)      0.165     1.07 (0.93--1.23)   0.318     152 (4.6)   1.11 (0.83--1.48)   0.481     1.06 (0.78--1.45)   0.710
   ≥20 g/day in women, ≥40 g/day in men      1,271           622 (48.9)              1.73 (1.49--2.01)      \<0.001   1.29 (1.08--1.54)   0.005     92 (7.2)    1.81 (1.32--2.49)   \<0.001   1.36 (0.94--1.97)   0.104
  Metabolic syndrome                                                                                        \<0.001                       \<0.001                                   \<0.001                       0.036
   Absent                                    4,781           1,716 (35.9)            1                                1                             204 (4.3)   1                             1                   
   Present                                   1,570           781 (49.7)              1.77 (1.58--1.98)                1.29 (1.13--1.47)             112 (7.1)   1.72 (1.36--2.19)             1.34 (1.02--1.76)   
  Gastric pathology                                                                                         0.071                         0.347                                     0.938                         0.938
   Absent                                    6,296           2,467 (39.2)            1                                1                             313 (5.0)   1                             1                   
   Gastric adenoma                           32              18 (56.3)               2.00 (0.99--4.02)      0.053     1.57 (0.77--3.23)   0.212     2 (6.3)     1.27 (0.30--5.34)   0.741     1.00 (0.24--4.25)   0.998
   High-grade dysplasia or invasive cancer   23              12 (52.2)               1.69 (0.75--3.84)      0.208     1.38 (0.59--3.21)   0.450     1 (4.3)     0.87 (0.12--6.47)   0.869     0.69 (0.09--5.20)   0.721

Data are presented as odds ratio (95% confidence interval). Logistic regression was used for the assessment of the risk factors.

*H. pylori*, *Helicobacter pylori*; CRN, colorectal neoplasm; CRC, colorectal cancer.

###### 

Association between *Helicobacter pylori* Infection, Atrophic Gastritis, and Colorectal Neoplasm

                          *H. pylori* (−) AG (−) (n=2,148)   *H. pylori* (−) AG (+) (n=307)   *H. pylori* (+) AG (−) (n=2,214)   *H. pylori* (+) AG (+) (n=1,682)                                                                                           
  ----------------------- ---------------------------------- -------------------------------- ---------------------------------- ---------------------------------- --------- -------------- ------------------- ------- -------------- ------------------- ---------
  Age, mean±SD, yr        49.8±7.1                                                            59.2±9.5                                                                        49.8±6.7                                   55.2±8.6                           
  Male sex                1,037 (48.2)                                                        176 (57.3)                                                                      1,124 (50.8)                               1,017 (60.5)                       
  Overall CRN             728 (33.9)                         1                                136 (44.3)                         1.55 (1.22--1.98)                  \<0.001   825 (37.3)     1.15 (1.02--1.31)   0.020   808 (48.0)     1.80 (1.58--2.05)   \<0.001
  Advanced CRN            95 (3.9)                           1                                17 (5.5)                           1.56 (0.91--2.67)                  0.108     98 (4.4)       1.23 (0.91--1.67)   0.183   123 (7.3)      2.09 (1.56--2.80)   \<0.001
   Villous adenoma        13 (0.5)                           1                                2 (0.7)                            1.27 (0.28--5.78)                  0.754     11 (0.5)       0.97 (0.42--2.24)   0.943   21 (1.2)       2.46 (1.18--5.11)   0.016
   ≥1 cm sized adenoma    85 (3.5)                           1                                15 (4.9)                           1.53 (0.86--2.69)                  0.147     82 (3.7)       1.14 (0.83--1.58)   0.423   103 (6.1)      1.94 (1.42--2.64)   \<0.001
   High-grade dysplasia   11 (0.4)                           1                                4 (1.3)                            4.04 (1.18--13.87)                 0.027     17 (0.8)       2.37 (0.98--5.72)   0.056   23 (1.4)       4.24 (1.82--9.91)   0.001
   ≥3 adenomas            132 (5.4)                          1                                31 (10.1)                          2.28 (1.49--3.47)                  \<0.001   141 (6.4)      1.38 (1.06--1.79)   0.017   185 (11.0)     2.51 (1.95--3.22)   \<0.001
  Any proximal CRN        441 (20.5)                         1                                91 (29.6)                          1.63 (1.25--2.13)                  \<0.001   524 (23.7)     1.20 (1.04--1.39)   0.013   563 (33.5)     1.95 (1.68--2.25)   \<0.001

Logistic regression was used to analyze the association between *H. pylori* infection, AG, and CRN.

*H. pylori*, *Helicobacter pylori*; AG, atrophic gastritis; OR, odds ratio; CI, confidence interval; CRN, colorectal neoplasm.

###### 

Logistic Regression Model of the Association between *Helicobacter pylori* Infection, Atrophic Gastritis, and Colorectal Neoplasm after Adjustments for Confounding Factors[\*](#tfn8-gnl-10-902){ref-type="table-fn"}

                          *H. pylori* (−) AG (−)(n=2,148) OR (95% CI)   *H. pylori* (−) AG (+) (n=307)   *H. pylori* (+) AG (−) (n=2,214)   *H. pylori* (+) AG (+) (n=1,682)                               
  ----------------------- --------------------------------------------- -------------------------------- ---------------------------------- ---------------------------------- ------- ------------------- -------
  Overall CRN             1                                             0.85 (0.65--1.11)                0.222                              1.13 (0.99--1.29)                  0.057   1.24 (1.07--1.42)   0.003
  Advanced CRN            1                                             0.86 (0.49--1.52)                0.609                              1.17 (0.86--1.60)                  0.305   1.40 (1.03--1.91)   0.030
   Villous adenoma        1                                             1.01 (0.21--4.79)                0.989                              0.93 (0.40--2.16)                  0.871   2.00 (0.93--4.30)   0.076
   ≥1 cm sized adenoma    1                                             0.78 (0.43--1.42)                0.418                              1.09 (0.79--1.51)                  0.606   1.24 (0.89--1.71)   0.207
   High-grade dysplasia   1                                             2.40 (0.66--8.71)                0.180                              2.22 (0.92--5.38)                  0.077   2.91 (1.22--6.98)   0.017
   ≥3 adenomas            1                                             0.88 (0.55--1.39)                0.588                              1.29 (0.98--1.69)                  0.069   1.39 (1.06--1.83)   0.017
  Any proximal CRN        1                                             0.82 (0.61--1.09)                0.182                              1.17 (1.01--1.36)                  0.036   1.29 (1.10--1.51)   0.002

Logistic regression was used to analyze the data.

*H. pylori*, *Helicobacter pylori*; AG, atrophic gastritis; OR, odds ratio; CI, confidence interval; CRN, colorectal neoplasm.

Adjustments were performed by incorporating all of the relevant factors, such as age, gender, family history of colorectal cancer, body mass index, metabolic syndrome, pack-years of smoking, and level of alcohol consumption, into the analysis.

[^1]: Ji Young Lee and Hye Won Park contributed equally to this work as first authors.
